middle.news
Vectus Secures Cardinal Health for US FDA Pathway on VB0004
9:53am on Monday 13th of July, 2026 AEST
•
Biotechnology
Read Story
Vectus Secures Cardinal Health for US FDA Pathway on VB0004
9:53am on Monday 13th of July, 2026 AEST
Key Points
Cardinal Health appointed as US FDA regulatory agent
VB0004 targets idiopathic pulmonary fibrosis with first-in-class oral therapy
FDA submissions include Orphan Drug Designation and IND application
Phase Ia trial completed with favourable safety profile
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Vectus Biosystems (ASX:VBS)
OPEN ARTICLE